Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

被引：11

作者：

Olszewski, Adam J. ^{[1
]}

Eradat, Herbert ^{[2
]}

Avigdor, Abraham ^{[3
,4
]}

Horowitz, Netanel A. ^{[5
]}

Babu, Sunil ^{[6
]}

Levi, Itai ^{[7
]}

McKinney, Matthew ^{[8
]}

Lee, Seung Tae ^{[9
]}

Bergua Burgues, Juan Miguel ^{[10
]}

Rodriguez Izquierdo, Antonia ^{[11
]}

Bastos-Oreiro, Mariana ^{[12
]}

Ganzel, Chezi ^{[13
,14
]}

Kim, Tae Min ^{[15
]}

Jeon, Youngwoo ^{[16
]}

Taszner, Michal ^{[17
]}

Narkhede, Mayur ^{[18
]}

Kim, Won Seog ^{[19
]}

Shin, Ho-Jin ^{[20
]}

Lavie, David ^{[21
]}

Woszczyk, Dariusz ^{[22
]}

Dunshee, Diana ^{[23
]}

Kapp, Amy V. ^{[23
]}

Zhou, Mingzhu ^{[24
]}

Batlevi, Connie Lee ^{[23
]}

Ead, Wahib ^{[23
]}

Sellam, Gila ^{[25
]}

Jurczak, Wojciech ^{[26
]}

机构：

[1] Brown Univ, Providence, RI USA

[2] Univ Calif Los Angeles, Los Angeles, CA USA

[3] Sheba Med Ctr, Ramat Gan, Israel

[4] Tel Aviv Univ, Sch Med, Tel Aviv, Israel

[5] Technion, Rambam Hlth Care Campus, Haifa, Israel

[6] Ft Wayne Med Oncol & Hematol, Ft Wayne, IN USA

[7] Soroka Univ Med Ctr, Beer Sheva, Israel

[8] Duke Canc Inst, Durham, NC USA

[9] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD USA

[10] San Pedro Alcantara Hosp, Hematol & Hemotherapy Serv, Caceres, Spain

[11] Univ Hosp October, Madrid, Spain

[12] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[13] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel

[14] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel

[15] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[16] Yeouido St Marys Hosp, Lymphoma & Cell Therapy Res Ctr, Seoul, South Korea

[17] Med Univ Gdansk, Univ Clin Ctr, Dept Hematol & Transplantol, Gdansk, Poland

[18] Univ Alabama Birmingham, Birmingham, AL USA

[19] Sungkyunkwan Univ, Sch Med, Seoul, South Korea

[20] Pusan Natl Univ, Pusan Natl Univ Hosp, Biochem Res Inst,Sch Med, Dept Internal Med,Div Hematol Oncol, Busan, South Korea

[21] Hadassah Med Ctr, Jerusalem, Israel

[22] Univ Opole, Prov Hosp, Opole, Poland

[23] Genentech Inc, San Francisco, CA USA

[24] F Hoffmann La Roche Ltd, Shanghai, Peoples R China

[25] F Hoffmann La Roche Ltd, Basel, Switzerland

[26] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177588

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[41] Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma
Lu, Tong
Gibiansky, Leonid
Li, Xiaobin
Li, Chunze
Shi, Rong
Agarwal, Priya
Hirata, Jamie
Miles, Dale
Chanu, Pascal
Girish, Sandhya
Jin, Jin Yan
Lu, Dan
LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2905 - 2914
[42] Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study
Tilly, Herve
Morschhauser, Franck
Bartlett, Nancy L.
Mehta, Amitkumar
Salles, Gilles
Haioun, Corinne
Munoz, Javier
Chen, Andy I.
Kolibaba, Kathryn
Lu, Dan
Yan, Mark
Penuel, Elicia
Hirata, Jamie
Lee, Calvin
Sharman, Jeff P.
LANCET ONCOLOGY, 2019, 20 (07): : 998 - 1010
[43] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation
Bartlett, Nancy L.
Chen, Andy I.
Kolibaba, Kathryn S.
Lamy, Thierry
Jones, Surai
Hirata, Jamie
Sharman, Jeff P.
BLOOD, 2015, 126 (23)
[44] The POLARIX Study: Polatuzumab Vedotin With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone vs Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
[45] Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Fu, Yu-Hua
Wu, Shang-Ju
Tan, Elise Chia-Hui
Wang, Chi-Chuan
Kim, Kibum
Chou, Wen-Chien
Lin, Fang-Ju
BLOOD, 2022, 140 : 10808 - 10809
[46] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
Vodicka, Prokop
Benesova, Katerina
Janikova, Andrea
Prochazka, Vit
Belada, David
Mocikova, Heidi
Steinerova, Katerina
Duras, Juraj
Karban, Josef
Hanackova, Veronika
Sykorova, Alice
Obr, Ales
Trneny, Marek
EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
[47] US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
Betts, Keith A.
Thuresson, Per-Olof
Felizzi, Federico
Du, Ella X.
Dieye, Ibou
Li, Jia
Schulz, Mathias
Masaquel, Anthony S.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (14) : 1003 - 1015
[48] Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
Russler-Germain, David A.
Cliff, Edward R. Scheffer
Bartlett, Nancy L.
BLOOD, 2023, 142 (25) : 2216 - 2219
[49] Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
Zhang, Yian
Yuan, Ling
Zhuang, Jingli
Wang, Zhimei
Zhang, Xuejiao
Wang, Weiguang
Liu, Peng
BLOOD, 2023, 142
[50] Prognostic nomogram for overall survival in previously untreated patients with diffuse large B-cell lymphoma
Han, Y.
Qin, Y.
Liu, P.
Yang, J.
He, X.
Zhou, S.
Gui, L.
Yang, S.
Zhang, C.
Huang, Y.
Jiang, S.
Shi, Y.
Wang, Q.
Sun, Y.
Shi, Y-K.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →